Item Details

abstract

Prostate cancer is the most common non-skin cancer in American men. At the current time, there is no effective treatment for men with metastatic prostate cancer. Androgen ablation is the most successful systemic treatment for prostate cancer. However, the cancer eventually recurs as androgen-independent prostate cancer. Phosphoinositide 3-kinases (PI3Ks) are involved in several imperative cellular functions such as growth and survival; therefore, inhibition of PI3K induces apoptosis (programmed cell death) and suppresses tumor growth. Several compounds have been identified as PI3K inhibitors, e.g., wortmannin, LY294002, and, ZSTK474, but all have low selectivity. We have addressed the specificity of current PI3K inhibitors by developing PSA (prostate-specific antigen)-activated analogues of known PI3K inhibitors LY294002 and ZSTK474.

subject

LY294002

PI3K inhibitor

ZSTK474

contributor

Pinder, Tanya (author)

Welker, Mark E. (committee chair)

Kulik, George (committee member)

Alexander, Rebecca W. (committee member)

Colyer, Christa L. (committee member)

Wright, Marcus W. (committee member)

date

2012-06-12T08:36:05Z (accessioned)

2013-06-12T08:30:11Z (available)

2012 (issued)

degree

Chemistry (discipline)

embargo

2013-06-12 (terms)

identifier

http://hdl.handle.net/10339/37309 (uri)

language

en (iso)

publisher

Wake Forest University

title

SYNTHESIS AND SCREENING OF PI3K INHIBITOR PRODRUGS FOR TREATMENT OF PROSTATE CANCER

type

Dissertation